Navigation Links
Hard to Treat Diseases (HTDS.PK) Business Summary Update
Date:12/7/2009

ds or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain
2. New study finds barriers to pain treatment in children with sickle cell disease
3. Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
4. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
5. New Gene Findings Will Help Guide Treatment in Infant Leukemia
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care
8. Epilepsy patients caught in treatment gap are not getting state-of-the-art care
9. Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations
10. Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance
11. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 As the ... working with its partners to both purchase critical emergency supplies ... the US to Liberia. These supplies will contain materials used ... the most heavily populated areas of the country. , ... involved in the response to the Ebola outbreak in the ...
(Date:7/29/2014)... 29, 2014 The Board of Governors of ... Hart LLP ’s Connie Akridge to serve as ... as President of the Foundation. Akridge served as President of ... a partner at Holland & Hart in Las Vegas, providing ... matters to insurance and healthcare clients for more than 25 ...
(Date:7/29/2014)... 2014 CarePoint Health is proud ... our network, CarePoint Health Medical Group. Our system ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ... represents CarePoint Health’s commitment to provide the highest ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... behalf of individuals who allegedly suffered serious liver ... continue to move forward in a multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to an ... certain deadlines pertaining to bellwether case and ...
(Date:7/29/2014)... Denham Springs, LA (PRWEB) July 29, 2014 ... long holiday across the United States usually celebrated throughout ... More recently though, those summer days now mark the ... increase in crashes involving teen drivers. In 2012 ... drivers during the period from Memorial Day to Labor ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... Blue Shield of,Minnesota (Blue Cross) today released its financial ... of 0.3 percent ($25.1 million) on,full-year revenues of $8.4 ... offset $104 million in operating losses. Blue,Cross remains financially ... claims and operating expenses., More than 90 cents ...
... THURSDAY, April 17 (HealthDay News) -- The antidepressant Prozac ... their more plastic youthful condition in animal experiments, researchers ... new explanation for the antidepressant activity of the medication ... be used to treat other conditions caused by malfunction ...
... WASHINGTON, April 17 The Better Hearing,Institute (BHI) announced ... ( http://www.hearingcheck.org ), a nationwide campaign to,help millions of ... to,unaddressed hearing loss. The campaign will serve as the ... during the month of May., Spouses, Baby Boomers ...
... to improve ... patient access, HARRISBURG, Pa., April ... of Philadelphia as,its new president. Dr. Gamba, who served as president-elect for ... be a major focus of the organization., "All Pennsylvanians deserve access ...
... (Nasdaq: CTGX ),an international information technology (IT) solutions ... 2008 first quarter,financial results on April 23, 2008 after ... to discuss its financial results and business,strategy on Thursday, ... and Chief Executive Officer James R. Boldt will lead ...
Cached Medicine News:Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2007 Financial Results 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:Better Hearing Institute Kicks Off the Across America Hearing Check Challenge for Better Hearing and Speech Month, Bringing Better Quality of Life Back to Millions of Americans 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:CTG Announces 2008 First Quarter Conference Call and Webcast Information 2
(Date:7/29/2014)... July 29, 2014 Amgen (NASDAQ: ... quarter of 2014. Key results include: , Total ... percent product sales growth driven by strong performance across ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... to $2.37, driven by higher revenues and a significant ...
(Date:7/29/2014)... Inc. (NASDAQ: SQNM ), a life sciences ... revenues of $39.8 million for the second quarter of ... $24.5 million for the second quarter of 2013. ... on May 30, 2014, has been accounted for as ... excluded from continuing operations for all periods. ...
(Date:7/29/2014)... July 29, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... public offering of 8,333,333 shares of its common  stock at ... of the common stock was offered by Pfenex. In addition, ... up to 1,250,000 additional shares of common stock at the ... traded on the NYSE MKT under the symbol "PFNX." ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12
... role within the orthopaedic industry, DePuy Orthopaedics ... industry's leading fixed-bearing implant, the P.F.C. SIGMA ... clinically proven technology of the LCS Knee ... ,The result is the P.F.C. SIGMA RP ...
The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i...
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
Medicine Products: